Y. Sonehara

Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea

M. Ogura, K. Tobinai, T. Uchida, 2020, Japanese journal of clinical oncology.

Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma

T. Yamauchi, K. Izutsu, Y. Kwong, 2023, Journal of clinical and experimental hematopathology : JCEH.

Pharmacodynamics and Pharmacokinetics of AMG 531, a Thrombopoiesis‐Stimulating Peptibody, in Healthy Japanese Subjects: A Randomized, Placebo‐Controlled Study

T. Fujita, Y. Kumagai, Machiko Ozaki, 2007, Journal of clinical pharmacology.

Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

K. Izutsu, Y. Kwong, H. Kang, 2021, Blood.

Standardization of [F-18]FDG PET/CT for response evaluation by the Radiologic Society of North America-Quantitative Imaging Biomarker Alliance (RSNA-QIBA) profile: preliminary results from the Japan-QIBA (J-QIBA) activities for Asian international multicenter phase II trial

Kazunori Kubota, U. Tateishi, J. Tsuchiya, 2018, Japanese Journal of Radiology.

A Phase 2 Open-Label, Sequential-Cohort, Dose-Escalation Study of AMG 531 in Japanese Patients with Chronic Immune Thrombocytopenic Purpura (ITP).

T. Nagasawa, K. Ando, S. Hashino, 2007 .

Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study

K. Izutsu, Y. Kwong, H. Kang, 2023, Blood advances.